Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Johnson & Johnson
(NY:
JNJ
)
145.74
+0.97 (+0.67%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Johnson & Johnson
< Previous
1
2
3
4
5
6
7
8
9
...
91
92
Next >
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
March 20, 2024
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual...
Via
Benzinga
Jim Cramer Reveals Nvidia's Non-Tech Partners That Can Be Potential Market Winner: 'Best Opportunities'
March 19, 2024
CNBC host Jim Cramer has spotlighted several lesser-known partners of Nvidia that could potentially benefit from the company's advanced artificial intelligence technology.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
7 Defensive Stocks to Build a Moat Around Your Portfolio
March 19, 2024
Although the market seems to continuously be on the rise, some concerning data suggests investors should consider defensive stocks.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
March 19, 2024
Via
Benzinga
Analyzing NYSE:JNJ's Dividend Potential.
March 13, 2024
Why JOHNSON & JOHNSON (NYSE:JNJ) qualifies as a good dividend investing stock.
Via
Chartmill
Insights Into Johnson & Johnson's Performance Versus Peers In Pharmaceuticals Sector
March 11, 2024
Via
Benzinga
Johnson & Johnson Unusual Options Activity For March 08
March 08, 2024
Via
Benzinga
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
March 18, 2024
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &...
Via
Benzinga
Exposures
Product Safety
Guardians of Your Golden Years: 7 Stocks Every Retiree Needs to Own
March 16, 2024
Investing in your golden years is about choosing stocks for retirees that are low-risk, offer passive income and steadily grow.
Via
InvestorPlace
Meet the "Magnificent Seven" Stock That Pays More Dividends Than Any Other U.S.-Based Company
March 16, 2024
Microsoft is the complete package.
Via
The Motley Fool
Johnson & Johnson Stock Is Great. Here's Why You Shouldn't Buy It.
March 16, 2024
Johnson & Johnson's days of being a top healthcare stock could be long gone.
Via
The Motley Fool
The Taxman Cometh: 3 Stocks to Soften the Blow and Grow Your Dough
March 15, 2024
Dive into tax season stocks, featuring dividend-rich JNJ and EQIX, plus growth-focused TSLA, for a smarter tax season strategy.
Via
InvestorPlace
Why Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says Analyst
March 15, 2024
Fellow infant formula maker Reckitt Benckiser was ordered to pay $60 million to a mother whose baby died after eating Enfamil.
Via
Investor's Business Daily
Topics
Death
Exposures
Death
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
March 14, 2024
Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target...
Via
Benzinga
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
March 14, 2024
Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications.
Via
Benzinga
Topics
Bankruptcy
Lawsuit
Exposures
Financial
Glyphosate
Legal
The 3 Most Undervalued Healthcare Stocks to Buy in March 2024
March 14, 2024
Wager on these promising undervalued healthcare stocks, catering to investors aiming to leverage growth within the dynamic healthcare space.
Via
InvestorPlace
Top Stock Reports For UnitedHealth, Johnson & Johnson & Oracle
March 13, 2024
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc. (UNH), Johnson & Johnson (JNJ) and Oracle Corp. (ORCL).
Via
Talk Markets
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
March 13, 2024
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into...
Via
Benzinga
Exposures
Product Safety
3 No-Brainer Stocks to Buy With $300 Right Now
March 13, 2024
A reasonably modest amount of money can go a long way when it's put to work in historically cheap, industry-leading businesses.
Via
The Motley Fool
7 High-Quality Blue-Chip Stocks to Buy if You’re Looking for Stability
March 12, 2024
With the market facing a possible rotation out of hot tech names, these stable blue-chip stocks may offer investors confidence.
Via
InvestorPlace
Golden Cross Alert: Johnson & Johnson Shines With Ambrx Deal, Bullish Technical Signal
March 12, 2024
Johnson & Johnson stock down 1.22% in 6 months, up 5.57% in a year, and 3% YTD. Recent acquisition of Ambrx Biopharma boosts stock. Golden Cross signals trend reversal.
Via
Benzinga
3 Must-Have Dividend Kings for a Steady Income Stream
March 12, 2024
Discover the dividend kings with constant growth, dominating pharmaceuticals, household products and biotechnology industries.
Via
InvestorPlace
2 High-Yield Dow Jones Dividend Stocks to Buy Now and Hold Forever
March 12, 2024
These industry leaders boast advantages that could expand their bottom lines for decades.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
The Dow’s Best Friends: 3 ‘Dogs’ Ready to Fetch Huge Returns
March 11, 2024
The Dogs of the Dow strategy is one of the best yearly strategies investors should use to make some good money.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Wall Street Favorites: Why Analysts Love These 3 Blue-Chip Stocks
March 11, 2024
Blue-chip stocks are known for their quality, stablility and consistency, which you'll find in all three of these top-notch growth stocks.
Via
InvestorPlace
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
March 11, 2024
These are some of the best-performing stocks in what's arguably society's most important industry.
Via
The Motley Fool
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
March 09, 2024
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung...
Via
Talk Markets
Exposures
Product Safety
The Top 3 Pharma Stocks to Buy in March2024
March 09, 2024
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge.
Via
InvestorPlace
3 Dividend Aristocrat Stocks to Buy And Hold: March 2024
March 08, 2024
Buy-and-holder investors should fill their portfolios with these dividend aristocrat stocks to buy. These are some of the top names in the market.
Via
InvestorPlace
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
March 07, 2024
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
91
92
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.